Logo image of NMTC

NEUROONE MEDICAL TECHNOLOGIE (NMTC) Stock Fundamental Analysis

NASDAQ:NMTC - Nasdaq - US64130M2098 - Common Stock - Currency: USD

0.6236  +0.01 (+1.55%)

After market: 0.63 +0.01 (+1.03%)

Fundamental Rating

2

Taking everything into account, NMTC scores 2 out of 10 in our fundamental rating. NMTC was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NMTC have multiple concerns. While showing a medium growth rate, NMTC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NMTC had negative earnings in the past year.
NMTC had a negative operating cash flow in the past year.
NMTC had negative earnings in each of the past 5 years.
NMTC had a negative operating cash flow in each of the past 5 years.
NMTC Yearly Net Income VS EBIT VS OCF VS FCFNMTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -110.68%, NMTC is not doing good in the industry: 83.07% of the companies in the same industry are doing better.
NMTC's Return On Equity of -244.88% is on the low side compared to the rest of the industry. NMTC is outperformed by 77.78% of its industry peers.
Industry RankSector Rank
ROA -110.68%
ROE -244.88%
ROIC N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
NMTC Yearly ROA, ROE, ROICNMTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

NMTC has a Gross Margin of 65.61%. This is in the better half of the industry: NMTC outperforms 67.72% of its industry peers.
The Profit Margin and Operating Margin are not available for NMTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMTC Yearly Profit, Operating, Gross MarginsNMTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

3

2. Health

2.1 Basic Checks

NMTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
NMTC has more shares outstanding than it did 1 year ago.
NMTC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NMTC is higher compared to a year ago.
NMTC Yearly Shares OutstandingNMTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NMTC Yearly Total Debt VS Total AssetsNMTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -12.14, we must say that NMTC is in the distress zone and has some risk of bankruptcy.
NMTC has a worse Altman-Z score (-12.14) than 81.48% of its industry peers.
A Debt/Equity ratio of 0.60 indicates that NMTC is somewhat dependend on debt financing.
NMTC has a Debt to Equity ratio of 0.60. This is in the lower half of the industry: NMTC underperforms 66.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z -12.14
ROIC/WACCN/A
WACC8.74%
NMTC Yearly LT Debt VS Equity VS FCFNMTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 3.64 indicates that NMTC has no problem at all paying its short term obligations.
The Current ratio of NMTC (3.64) is better than 62.96% of its industry peers.
NMTC has a Quick Ratio of 2.41. This indicates that NMTC is financially healthy and has no problem in meeting its short term obligations.
NMTC has a Quick ratio (2.41) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.64
Quick Ratio 2.41
NMTC Yearly Current Assets VS Current LiabilitesNMTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

NMTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.46%, which is quite impressive.
Looking at the last year, NMTC shows a very strong growth in Revenue. The Revenue has grown by 205.91%.
NMTC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.22% yearly.
EPS 1Y (TTM)61.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
Revenue 1Y (TTM)205.91%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%234.48%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year90%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMTC Yearly Revenue VS EstimatesNMTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
NMTC Yearly EPS VS EstimatesNMTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NMTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMTC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTC Price Earnings VS Forward Price EarningsNMTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTC Per share dataNMTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NMTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROONE MEDICAL TECHNOLOGIE

NASDAQ:NMTC (4/30/2025, 8:25:01 PM)

After market: 0.63 +0.01 (+1.03%)

0.6236

+0.01 (+1.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12 2025-02-12/bmo
Earnings (Next)05-08 2025-05-08/amc
Inst Owners16.79%
Inst Owner Change4.11%
Ins Owners11.08%
Ins Owner Change4.83%
Market Cap29.55M
Analysts43.33
Price TargetN/A
Short Float %1.03%
Short Ratio1.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)62.01%
Min EPS beat(2)-34.8%
Max EPS beat(2)158.82%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-17.91%
Min Revenue beat(2)-88.49%
Max Revenue beat(2)52.66%
Revenue beat(4)1
Avg Revenue beat(4)-28.94%
Min Revenue beat(4)-88.49%
Max Revenue beat(4)52.66%
Revenue beat(8)4
Avg Revenue beat(8)6.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.38
P/FCF N/A
P/OCF N/A
P/B 10.07
P/tB 10.28
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.18
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -110.68%
ROE -244.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.61%
FCFM N/A
ROA(3y)-151.29%
ROA(5y)-173.14%
ROE(3y)-597.5%
ROE(5y)-520.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.35
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.46%
Cap/Sales 1.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.64
Quick Ratio 2.41
Altman-Z -12.14
F-Score4
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)158.25%
Cap/Depr(5y)160.45%
Cap/Sales(3y)9.28%
Cap/Sales(5y)12.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%142.86%
EPS Next Y33.33%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)205.91%
Revenue growth 3Y143.22%
Revenue growth 5YN/A
Sales Q2Q%234.48%
Revenue Next Year90%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y17.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.03%
OCF growth 3YN/A
OCF growth 5YN/A